Acute Myeloid leukemia (AML) is a multifaceted hematologic malignancy characterized by a diverse range of prognoses. Using 16-plex TMT-LC/LC-MS/MS, we focused on a group of proteins that showed upregulated expression in patients with peripheral blood diseases compared to healthy controls. These proteins included HMGA1, HNRNPU, HMGN2, H1-2, RCC1, H3-2, and H1-5. These proteins are implicated in essential biological processes such as Spliceosome assembly, Nucleotide excision repair mechanism, and Ribosome biogenesis. In addition, it was shown that ZNF207, SYNCRIP, HMGA1, HNRNPU, HMGN3, RPL26, COA6, COA5, and IER2 exhibited notable variations in expression levels when comparing peripheral blood disorders and peripheral blood illnesses. This finding implies that these genes may have a potential use in the diagnosis of AML. The proteins identified in this study were shown to be associated with the KEGG pathways of Hematopoietic cell lineage, Spliceosome and ATP-dependent chromatin remodeling. Also, using ELISA, we examined the influence exerted by the initial levels of JAK/STAT, AKT, TIM3, IDH1, and IDH2 expressions on the overall survival outcomes of patients diagnosed with AML. The results of our study indicate that the protein expression levels examined do not have a significant impact on the outcomes of patients with AML. However, it is important to note that these findings may differ from past studies, highlighting the need for more investigation in this area. The overexpression of these proteins may be responsible for the possible improvement of prognostic outcomes in patients with AML. To demonstrate a correlation between crucial indicators and the prognosis of AML, next investigations must prioritize the inclusion of research trials including significant participant cohorts. This approach will provide a more comprehensive comprehension of the complicated nature of this illness and its prognostic implications.